Alpha Cognition (OTC:ACOGF) Hits New 12-Month High – Here’s Why

Alpha Cognition Inc. (OTC:ACOGF) hit a new 52-week high on Monday . The company traded as high as C$8.91 and last traded at C$8.40, with a volume of 4246 shares trading hands. The stock had previously closed at C$8.60.

Alpha Cognition Stock Performance

The stock has a market cap of C$1.27 billion, a P/E ratio of -70.00 and a beta of 2.80. The stock’s 50-day moving average is C$1.05 and its 200-day moving average is C$0.71.

Alpha Cognition (OTC:ACOGF) last announced its quarterly earnings data on Monday, August 12th. The company reported C($0.01) earnings per share for the quarter, beating the consensus estimate of C($0.04) by C$0.03. On average, equities analysts forecast that Alpha Cognition Inc. will post -0.19 EPS for the current year.

Alpha Cognition Company Profile

Alpha Cognition Inc, a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.